The estimated Net Worth of Capital Partners Llc Rouhan... is at least $64.4 Million dollars as of 3 May 2021. Capital Rouhan owns over 80,000 units of Abeona Therapeutics Inc stock worth over $61,933,242 and over the last 4 years Capital sold ABEO stock worth over $2,470,661.
Capital has made over 8 trades of the Abeona Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Capital sold 80,000 units of ABEO stock worth $160,800 on 3 May 2021.
The largest trade Capital's ever made was selling 320,000 units of Abeona Therapeutics Inc stock on 14 January 2021 worth over $659,200. On average, Capital trades about 125,000 units every 32 days since 2020. As of 3 May 2021 Capital still owns at least 11,079,292 units of Abeona Therapeutics Inc stock.
You can see the complete history of Capital Rouhan stock trades at the bottom of the page.
Over the last 15 years, insiders at Abeona Therapeutics Inc have traded over $4,486,735 worth of Abeona Therapeutics Inc stock and bought 427,809 units worth $1,765,143 . The most active insiders traders include Capital Partners Llc Rouhan..., Todd Wider, and Michael Amoroso. On average, Abeona Therapeutics Inc executives and independent directors trade stock every 50 days with the average trade being worth of $256,542. The most recent stock trade was executed by Mark Alvino on 17 June 2024, trading 25,890 units of ABEO stock currently worth $116,764.
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Abeona Therapeutics Inc executives and other stock owners filed with the SEC include: